주의력결핍 과잉행동장애(ADHD) 치료제 시장(2026-2030년)

The global attention deficit hyperactivity disorder (ADHD) drugs market is forecasted to grow by USD 6181.7 mn during 2025-2030, accelerating at a CAGR of 6.7% during the forecast period. The report on the global attention deficit hyperactivity disorder (ADHD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by enhanced diagnostic procedures for adult populations, technological innovations in sustained-release drug delivery systems, expansion of mental health advocacy and reimbursement policies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global attention deficit hyperactivity disorder (ADHD) drugs market is segmented as below:

By Product

• Stimulant
• Non-stimulant

By End-User

• Children
• Adults

By Distribution Channel

• Retail pharmacy
• Hospital pharmacy
• Online

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • The Netherlands
  • Spain
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the proliferation of non-stimulant pharmacological alternatives as one of the prime reasons driving the global attention deficit hyperactivity disorder (ADHD) drugs market growth during the next few years. Also, integration of telehealth and digital pharmacy distribution networks and strategic alliances and vertical integration in pharmaceutical supply chain will lead to sizable demand in the market.

The report on the global attention deficit hyperactivity disorder (ADHD) drugs market covers the following areas:

• Global attention deficit hyperactivity disorder (ADHD) drugs market sizing
• Global attention deficit hyperactivity disorder (ADHD) drugs market forecast
• Global attention deficit hyperactivity disorder (ADHD) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global attention deficit hyperactivity disorder (ADHD) drugs market vendors that include AJENAT PHARMACEUTICALS, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Aytu BioPharma Inc., Azurity Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Johnson and Johnson Services, Novartis AG, Otsuka Holdings Co. Ltd., Sandoz Group AG, SHIONOGI Co. Ltd., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Tris Pharma Inc., Viatris Inc.. Also, the global attention deficit hyperactivity disorder (ADHD) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market 2020 - 2024 ($ million)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Stimulant - Market size and forecast 2025-2030
• 8.4 Non-stimulant - Market size and forecast 2025-2030
• 8.5 Market opportunity by Product
  • Market opportunity by Product ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Children - Market size and forecast 2025-2030
• 9.4 Adults - Market size and forecast 2025-2030
• 9.5 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Distribution Channel

• 10.1 Market segments
• 10.2 Comparison by Distribution Channel
• 10.3 Retail pharmacy - Market size and forecast 2025-2030
• 10.4 Hospital pharmacy - Market size and forecast 2025-2030
• 10.5 Online - Market size and forecast 2025-2030
• 10.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 The Netherlands - Market size and forecast 2025-2030
  • 12.4.6 Spain - Market size and forecast 2025-2030
  • 12.4.7 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.5.7 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Australia - Market size and forecast 2025-2030
  • 12.6.2 Brazil - Market size and forecast 2025-2030
  • 12.6.3 South Africa - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Enhanced diagnostic procedures for adult populations
  • Technological innovations in sustained-release drug delivery systems
  • Expansion of mental health advocacy and reimbursement policies
• 13.2 Market challenges
  • Complex regulatory requirements and schedule II classifications
  • Chronic supply chain disruptions and shortages of raw materials
  • Emergence of digital therapeutics and holistic behavioral interventions
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Proliferation of non-stimulant pharmacological alternatives
  • Integration of telehealth and digital pharmacy distribution networks
  • Strategic alliances and vertical integration in pharmaceutical supply chain

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Amneal Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Business segments
  • Amneal Pharmaceuticals Inc. - Key news
  • Amneal Pharmaceuticals Inc. - Key offerings
  • Amneal Pharmaceuticals Inc. - Segment focus
  • SWOT
• 15.5 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Product / Service
  • Aurobindo Pharma Ltd. - Key offerings
  • SWOT
• 15.6 Aytu BioPharma Inc.
  • Aytu BioPharma Inc. - Overview
  • Aytu BioPharma Inc. - Product / Service
  • Aytu BioPharma Inc. - Key offerings
  • SWOT
• 15.7 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.8 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.9 Glenmark Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product / Service
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.10 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.11 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.12 Otsuka Holdings Co. Ltd.
  • Otsuka Holdings Co. Ltd. - Overview
  • Otsuka Holdings Co. Ltd. - Business segments
  • Otsuka Holdings Co. Ltd. - Key news
  • Otsuka Holdings Co. Ltd. - Key offerings
  • Otsuka Holdings Co. Ltd. - Segment focus
  • SWOT
• 15.13 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Product / Service
  • Sandoz Group AG - Key offerings
  • SWOT
• 15.14 SHIONOGI Co. Ltd.
  • SHIONOGI Co. Ltd. - Overview
  • SHIONOGI Co. Ltd. - Product / Service
  • SHIONOGI Co. Ltd. - Key offerings
  • SWOT
• 15.15 Supernus Pharmaceuticals Inc.
  • Supernus Pharmaceuticals Inc. - Overview
  • Supernus Pharmaceuticals Inc. - Product / Service
  • Supernus Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.16 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Tris Pharma Inc.
  • Tris Pharma Inc. - Overview
  • Tris Pharma Inc. - Product / Service
  • Tris Pharma Inc. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations